CIK 0001661059 · Non-accelerated filer<br>Smaller reporting company
NextCure, Inc.
Sign in to watch- Ticker
- NXTC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475231247
- Phone
- 240-399-4900
- Business address
- 2850 QUARRY LAKE DRIVE, SUITE 280, BALTIMORE, MD, 21209
- Open-market buys, last 90 days
- $77,590
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$77,590. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Kundu Sourav Sr VP, Dev. & Mfg. | Grant or award · Employee Stock Option (Right to Buy) | +66,125 | 66,125 | ||
| 2025-01-31 | Cobourn Steven P. Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +117,375 | 117,375 | ||
| 2025-01-31 | Richman Michael President & CEO | Grant or award · Employee Stock Option (Right to Buy) | +305,500 | 305,500 | ||
| 2024-06-20 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +18,700 | 18,700 | ||
| 2024-06-20 | KABAKOFF DAVID S Director | Grant or award · Stock Option (Right to Buy) | +28,050 | 28,050 | ||
| 2024-06-20 | Jones Elaine V Director | Grant or award · Stock Option (Right to Buy) | +18,700 | 18,700 | ||
| 2024-06-20 | Houston John G Director | Grant or award · Stock Option (Right to Buy) | +18,700 | 18,700 | ||
| 2024-06-20 | Feigal Ellen Director | Grant or award · Stock Option (Right to Buy) | +18,700 | 18,700 | ||
| 2024-06-20 | Borgman Anne Elizabeth Director | Grant or award · Stock Option (Right to Buy) | +18,700 | 18,700 | ||
| 2024-03-29 | Shaw Kevin G. Sr VP, General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +93,900 | 93,900 | ||
| 2024-03-29 | Richman Michael President & CEO | Grant or award · Employee Stock Option (Right to Buy) | +244,400 | 244,400 | ||
| 2024-03-29 | Myint Han Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +93,900 | 93,900 | ||
| 2024-03-29 | Mayer Timothy Chief Operating Officer | Grant or award · Employee Stock Option (Right to Buy) | +93,900 | 93,900 | ||
| 2024-03-29 | Langermann Sol Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +93,900 | 93,900 | ||
| 2024-03-29 | Kundu Sourav Sr VP, Dev. & Mfg. | Grant or award · Employee Stock Option (Right to Buy) | +52,900 | 52,900 | ||
| 2024-03-29 | Cobourn Steven P. Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +93,900 | 93,900 | ||
| 2024-01-31 | Shaw Kevin G. Sr VP, General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +66,125 | 66,125 | ||
| 2024-01-31 | Richman Michael President & CEO | Grant or award · Employee Stock Option (Right to Buy) | +305,500 | 305,500 | ||
| 2024-01-31 | Myint Han Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +117,375 | 117,375 | ||
| 2024-01-31 | Mayer Timothy Chief Operating Officer | Grant or award · Employee Stock Option (Right to Buy) | +117,375 | 117,375 |
Page 3 of 10 · 197 trades